Abstract：
This study aims to explore the value of nimodipine combined with Ginkgo biloba extract in improving cognitive function and daily living abilities in patients with Parkinson\'s disease. Clinical data from 551 patients with Parkinson\'s disease admitted to the Neurology Department of the Affiliated Hospital of Beihua University from January 2022 to December 2022 were retrospectively collected. Cognitive function and daily living abilities were assessed in patients before treatment, and a reevaluation was conducted after 12 weeks of medication. Patients treated solely with nimodipine were categorized into the monotherapy group, while patients treated with nimodipine combined with Ginkgo biloba extract were included in the combination group. After 1:1 propensity score matching, a total of 83 pairs of patients were matched, and differences in relevant indicators between the 2 groups were compared. The total effective rate of treatment in the combination group was 90.36%, which was higher than the control group at 72.29% (P < .05). However, after treatment, the observation group showed higher Mini-Mental State Examination and activities of daily living scores compared to the control group (P < .05). The combined treatment of nimodipine and Ginkgo biloba extract in patients with Parkinson\'s disease has a significant effect and can effectively improve cognitive function and enhance daily living abilities.
摘要：
本研究旨在探讨尼莫地平联合银杏叶提取物对改善帕金森病患者认知功能和日常生活能力的价值。回顾性收集2022年1月至2022年12月北华大学附属医院神经内科收治的551例帕金森病患者的临床资料。治疗前对患者进行认知功能和日常生活能力评估,药物治疗12周后进行再评估.仅使用尼莫地平治疗的患者被归类为单药治疗组，尼莫地平联合银杏叶提取物治疗的患者被纳入联合组。1:1倾向评分匹配后，共有83对患者配对，并比较两组间相关指标的差异。联合组治疗总有效率为90.36%,高于对照组的72.29%(P<0.05)。然而,治疗后,观察组简易精神状态量表评分和日常生活活动能力评分均高于对照组（P＜0．05）。尼莫地平联合银杏叶提取物治疗帕金森病疗效显著,可有效改善患者认知功能,增强日常生活能力。
